1229454-43-6

Basic information

• Product Name: 2-fluoro-3-benzyloxy-6-nitrotoluene
• Synonyms: 2-fluoro-3-benzyloxy-6-nitrotoluene
• CAS NO: 1229454-43-6
• Molecular Weight: 261.253
• Mol File: 1229454-43-6.mol

Chemical Properties

• CAS DataBase Reference: 2-fluoro-3-benzyloxy-6-nitrotoluene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-fluoro-3-benzyloxy-6-nitrotoluene(1229454-43-6)
• EPA Substance Registry System: 2-fluoro-3-benzyloxy-6-nitrotoluene(1229454-43-6)

Safety Data

• Hazardous Substances Data: 1229454-43-6(Hazardous Substances Data)

Upstream product

• 100-51-6 benzyl alcohol 
• 914348-35-9 1,2-difluoro-3-methyl-4-nitrobenzene 

Downstream Products

• 288386-04-9 4-fluoro-1H-indol-5-ol 
• 288385-88-6 4-fluoro-2-methyl-1H-indol-5-ol 

Relevant articles and documents

Preparation method of 4-fluoro-5-hydroxy-2-methyl-1H-indole

The invention provides a preparation method of 4-fluoro-5-hydroxy-2-methyl-1H-indole. The preparation method comprises the steps that 2-fluoro-3-halo-6-nitrotoluene is used as a raw material and subjected to a substitution reaction with alcohol to prepare 2-fluoro-3-GO substituent-6-nitrotoluene, then 2-fluoro-3-GO substituent-6-nitrotoluene is subjected to a condensation reaction with trimethyl orthoacetate or triethyl orthoacetate to obtain 1-(2-fluoro-3-GO substituent-6-nitrophenyl)-2-alkoxy propylene, and then 1-(2-fluoro-3-GO substituent-6-nitrophenyl)-2-alkoxy propylene is further subjected to a reduction-cyclization reaction to obtain 4-fluoro-5-hydroxy-2-methyl-1H-indole. The preparation method is safe and green, simple in operation, low in cost, high in selectivity and high in yield and purity of a final product.

Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease

The invention relates to novel organic compounds of formula (I), and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.